JP2007516966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007516966A5 JP2007516966A5 JP2006542741A JP2006542741A JP2007516966A5 JP 2007516966 A5 JP2007516966 A5 JP 2007516966A5 JP 2006542741 A JP2006542741 A JP 2006542741A JP 2006542741 A JP2006542741 A JP 2006542741A JP 2007516966 A5 JP2007516966 A5 JP 2007516966A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cancer
- synthetic peptide
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 110
- 239000003814 drug Substances 0.000 claims 56
- 206010028980 Neoplasm Diseases 0.000 claims 55
- 201000011510 cancer Diseases 0.000 claims 55
- 230000002163 immunogen Effects 0.000 claims 44
- 239000012634 fragment Substances 0.000 claims 42
- 210000004027 cell Anatomy 0.000 claims 39
- 239000000203 mixture Substances 0.000 claims 39
- 210000002865 immune cell Anatomy 0.000 claims 36
- 229940079593 drug Drugs 0.000 claims 34
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 27
- 208000032839 leukemia Diseases 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 14
- 210000004443 dendritic cell Anatomy 0.000 claims 10
- 230000028993 immune response Effects 0.000 claims 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 9
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 9
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 206010027406 Mesothelioma Diseases 0.000 claims 7
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 7
- 206010057644 Testis cancer Diseases 0.000 claims 7
- 230000015572 biosynthetic process Effects 0.000 claims 7
- 201000005202 lung cancer Diseases 0.000 claims 7
- 208000020816 lung neoplasm Diseases 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 201000003120 testicular cancer Diseases 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 210000002798 bone marrow cell Anatomy 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 6
- 210000002540 macrophage Anatomy 0.000 claims 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 4
- 108010088751 Albumins Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102000040856 WT1 Human genes 0.000 claims 4
- 108700020467 WT1 Proteins 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims 3
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 230000001900 immune effect Effects 0.000 claims 3
- 239000012642 immune effector Substances 0.000 claims 3
- 230000008105 immune reaction Effects 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000037029 cross reaction Effects 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000004963 pathophysiological condition Effects 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52595503P | 2003-12-01 | 2003-12-01 | |
| PCT/US2004/040347 WO2005053618A2 (en) | 2003-12-01 | 2004-11-30 | Synthetic hla binding peptide analogues and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007516966A JP2007516966A (ja) | 2007-06-28 |
| JP2007516966A5 true JP2007516966A5 (cg-RX-API-DMAC7.html) | 2008-01-17 |
Family
ID=34652399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006542741A Pending JP2007516966A (ja) | 2003-12-01 | 2004-11-30 | 合成hla結合ペプチド類似体及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7488718B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2478913A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007516966A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004294345B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2548135C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2402184T5 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005053618A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060127409A1 (en) * | 2003-12-01 | 2006-06-15 | Scheinberg David A | Bcr-abl vaccines and methods of use thereof |
| ES2402184T5 (es) * | 2003-12-01 | 2016-10-25 | Sloan-Kettering Institute For Cancer Research | Análogos de péptidos de unión a HLA sintéticos y sus usos |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| EP2565201B1 (en) | 2005-10-17 | 2014-11-26 | Sloan-Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| EP2010209B1 (en) * | 2006-04-10 | 2016-06-15 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| JP2010504332A (ja) * | 2006-09-19 | 2010-02-12 | ヒューマン バイオモレキュラル リサーチ インスティテュート | アルツハイマー病の診断方法及び遺伝子マーカー |
| MX352947B (es) * | 2007-02-27 | 2017-12-14 | Int Inst Cancer Immunology Inc | Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo. |
| US20100255020A1 (en) * | 2007-11-20 | 2010-10-07 | Nec Corporation | Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them |
| WO2009072610A1 (ja) * | 2007-12-05 | 2009-06-11 | International Institute Of Cancer Immunology, Inc. | 癌ワクチン組成物 |
| CA2760041A1 (en) * | 2008-05-14 | 2009-11-19 | Simons Haplomics Limited | Methods and compositions for the treatment of cancer |
| WO2012027379A2 (en) * | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| WO2013018778A1 (ja) | 2011-07-29 | 2013-02-07 | 独立行政法人理化学研究所 | ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物 |
| US9539299B2 (en) * | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
| EP3520810A3 (en) * | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| LT2945647T (lt) | 2013-01-15 | 2021-02-25 | Memorial Sloan Kettering Cancer Center | Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US20240408197A1 (en) * | 2015-11-20 | 2024-12-12 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treating cancer |
| HUE059694T2 (hu) | 2015-11-20 | 2022-12-28 | Memorial Sloan Kettering Cancer Center | Készítmény rák kezelésére |
| US20190209669A1 (en) | 2016-08-23 | 2019-07-11 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
| WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018101309A1 (ja) | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Wt1ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| EP3604325A4 (en) | 2017-03-30 | 2021-01-13 | Sumitomo Dainippon Pharma Co., Ltd. | WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| US12059463B2 (en) | 2017-10-24 | 2024-08-13 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| JP7162675B2 (ja) | 2018-09-28 | 2022-10-28 | 住友ファーマ株式会社 | 注射用組成物 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| KR20230009426A (ko) | 2020-05-12 | 2023-01-17 | 스미토모 파마 가부시키가이샤 | 암을 처치하기 위한 의약 조성물 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| TW202315645A (zh) | 2021-08-12 | 2023-04-16 | 日商癌免疫研究所股份有限公司 | 用以處置或預防癌症之醫藥組合物及方法 |
| CN114149970B (zh) * | 2021-11-09 | 2024-06-18 | 因诺伟(北京)生物医疗科技有限公司 | 一种外周血造血干细胞来源致敏树突状细胞的制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156316A (en) * | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| NZ521430A (en) * | 2000-02-22 | 2004-04-30 | Corixa Corp | Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma |
| ES2402184T5 (es) * | 2003-12-01 | 2016-10-25 | Sloan-Kettering Institute For Cancer Research | Análogos de péptidos de unión a HLA sintéticos y sus usos |
-
2004
- 2004-11-30 ES ES04812790.6T patent/ES2402184T5/es not_active Expired - Lifetime
- 2004-11-30 AU AU2004294345A patent/AU2004294345B2/en not_active Expired
- 2004-11-30 WO PCT/US2004/040347 patent/WO2005053618A2/en not_active Ceased
- 2004-11-30 EP EP11189059A patent/EP2478913A1/en not_active Withdrawn
- 2004-11-30 JP JP2006542741A patent/JP2007516966A/ja active Pending
- 2004-11-30 US US10/999,425 patent/US7488718B2/en not_active Expired - Lifetime
- 2004-11-30 CA CA2548135A patent/CA2548135C/en not_active Expired - Lifetime
- 2004-11-30 EP EP04812790.6A patent/EP1708732B2/en not_active Expired - Lifetime
-
2005
- 2005-09-12 US US11/223,139 patent/US7598221B2/en active Active
-
2009
- 2009-10-06 US US12/574,555 patent/US20100239547A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4480580B2 (ja) | Wt1置換型ペプチド | |
| EP2385117B1 (en) | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same | |
| DK2547364T3 (en) | Peptides, conjugates and methods for increasing the immunogenicity of a vaccine | |
| JP6367950B2 (ja) | 前立腺癌治療用組成物 | |
| JP6266811B2 (ja) | 血管新生病の免疫療法 | |
| WO2016146261A1 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine | |
| TWI455721B (zh) | 癌疫苗組合物 | |
| WO2005095598A1 (ja) | Wt1由来の癌抗原ペプチド | |
| EP3094652A1 (en) | Novel vaccines against hpv and hpv-related diseases | |
| JP2007516966A (ja) | 合成hla結合ペプチド類似体及びその使用方法 | |
| ES2805829T3 (es) | Péptido derivado de GPC3, composición farmacéutica para el tratamiento o la prevención de cáncer usando el mismo, inductor de inmunidad y método para producir células presentadoras de antígeno | |
| BRPI0708737A2 (pt) | mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural | |
| NO309798B1 (no) | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen | |
| BR112019018616A2 (pt) | peptídeos e métodos para o tratamento de diabetes | |
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| TW201000119A (en) | MYBL2 epitope peptides and vaccines containing the same | |
| CN109718363B (zh) | 预防、缓解或治疗阿尔茨海默病的肽及其应用 | |
| JP2022513209A (ja) | オリゴペプチドを有効成分として含むがんの予防または治療用薬学的組成物 | |
| AU2015365606B2 (en) | Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis | |
| CN101072875B (zh) | 新型癌抗原肽及其用途 | |
| US20160213746A1 (en) | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide | |
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| JP2001514659A (ja) | ドラスタチン−15誘導体とタキサンとの併用 | |
| JP2002538166A (ja) | Mhcクラスiiによって提示されるmage−3由来免疫原性ペプチドおよびその使用 | |
| WO2012015979A2 (en) | Hmgb1-derived peptides enhance immune response to antigens |